XOMA Reports Fourth Quarter and Full-Year 2020 Financial Results and Operating Highlights
March 10, 2021 07:30 ET
|
XOMA Corporation
Recognized revenue of $29.4 million Six assets in the Company’s milestone and royalty portfolio advanced to Phase 2 clinical development Completed $24.6 million Series A Perpetual Preferred Stock...
XOMA to Present at Upcoming Investor Conferences
February 23, 2021 16:05 ET
|
XOMA Corporation
EMERYVILLE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the following upcoming investor...
XOMA to Present at H.C. Wainwright Virtual BioConnect 2021 and Biotech Showcase Digital Conferences
January 04, 2021 16:05 ET
|
XOMA Corporation
EMERYVILLE, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences: H.C....
XOMA Announces Exercise of Green Shoe Option and Closes Preferred Stock Offering
December 21, 2020 17:00 ET
|
XOMA Corporation
EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced underwritten registered public...
XOMA Prices $22 Million Offering of Series A Cumulative Perpetual Preferred Stock
December 10, 2020 18:22 ET
|
XOMA Corporation
EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the pricing of its underwritten registered public offering of 880,000...
XOMA Announces Offering of Series A Cumulative Perpetual Preferred Stock
December 10, 2020 07:52 ET
|
XOMA Corporation
EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of shares...
XOMA Earns $2 Million Milestone from Takeda as Mezagitamab Advances into Phase 2 Development
November 16, 2020 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $2 million milestone payment from Takeda...
XOMA Earns First Milestone Payment from 2018 Royalty Purchase Agreement
November 11, 2020 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $1 million milestone payment from Agenus Inc. (NASDAQ:...
XOMA Highlights Recent Royalty Asset Portfolio Developments and Reports Third Quarter 2020 Financial Results
November 05, 2020 07:30 ET
|
XOMA Corporation
Company recently earned a $25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancerAn undisclosed partner entered Phase 2 development, triggering a $0.5...
XOMA Acquires Royalty Interest in Four Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance
November 03, 2020 07:30 ET
|
XOMA Corporation
EMERYVILLE, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), announced today it has acquired the rights to future milestone and royalty revenue due to Bioasis Technologies...